Albert Bourla, Pfizer CEO (AP Images)
Full steam ahead, Pfizer goes bargain hunting in an age of coronavirus — with a special focus on cancer and rare diseases
Pfizer made a splash this week with its plans to spend $500 million on Covid-19 research. But the pharma giant isn’t letting a pandemic interfere with the M&A it needs to fulfill its longterm mission.
In fact, the outbreak may even lend them a hand in finding clinical-stage assets for the pipeline — if only the biotech execs and boards they approach fully understand the position they’re in.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.